Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 6/20 | 0.42 |
| ▸ | ITGAV | P06756 | 6/20 | 0.42 |
| ▸ | THRA | P10827 | 4/20 | 0.35 |
| ▸ | THRB | P10828 | 4/20 | 0.35 |
| ▸ | PPARG | P37231 | 3/20 | 0.35 |
| ▸ | RXRA | P19793 | 2/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PCNA | P12004 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23984323 | 0.98 | ITGB3 (0.41) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL23153267 | 0.93 | ITGB3 (0.42) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL23153285 | 0.90 | ITGB3 (0.39) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL23153242 | 0.88 | ITGB3 (0.43) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL23153245 | 0.84 | ITGB3 (0.42) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL24063205 | 0.79 | ITGB3 (0.35) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL23975552 | 0.77 | ITGB3 (0.38) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL23975539 | 0.75 | ITGB3 (0.35) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL23984251 | 0.74 | ITGB3 (0.52) | ITGB3ITGAVTHRATHRBPPARG | |
| SCHEMBL24063119 | 0.74 | THRB (0.47) | ITGB3ITGAVTHRATHRBPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186551-B2 | Composition of scalable thyrointegrin antagonists with improved retention in tumors | NANOPHARMACEUTICALS LLC (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210340111-A1 | COMPOSITION OF SCALABLE THYROINTEGRIN ANTAGONISTS WITH IMPROVED RETENTION IN TUMORS | NANOPHARMACEUTICALS LLC | 2021-11-04 | — | — | US | disclosed |
| US-10961204-B1 | Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors | NANOPHARMACEUTICALS LLC (US) | 2021-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186551-B2 | Composition of scalable thyrointegrin antagonists with improved retention in tumors | EGFR, TEK, HDGF | ITGB3 853/4885ITGAV 377/4885THRA 62/4885 |
| US-20210340111-A1 | COMPOSITION OF SCALABLE THYROINTEGRIN ANTAGONISTS WITH IMPROVED RETENTION IN TUMORS | EGFR, TEK, HDGF | ITGB3 853/4885ITGAV 377/4885THRA 62/4885 |
| US-10961204-B1 | Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors | EGFR, GMFG, NTRK1 | ITGB3 710/4885ITGAV 415/4885THRA 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.